lineage, such as Th1, Th2, or Th17. 2 The regulation of proliferation of T cells is important to maintain the immune tolerance. Regulatory
T cells (Treg) or inhibitory molecules like Cytotoxic T Lymphocyte
Antigen (CTLA-4) suppress an exacerbated T cell response maintaining equilibrium and avoiding an autoimmune disease. 3, 4 CD28 and CTLA-4 are transmembrane homodimers glycoproteins belonging to immunoglobulin family. 5 CD28 is constitutively found in resting and activated T cells, among their functions the proper activation and proliferation, cytokines production like IL-2 and anti-apoptotic proteins expression that drive in T cell survival can be found. 5 CTLA-4 is expressed on activated T cells and constitutively in Treg cells contrary to CD28 that is constitutive in resting T cells. CTLA-4 mediates apoptosis antigen-specific, suppresses auto-reactive T cells and inhibits cellular cycle progression and transcription factors such as NF-κB, NF-AT, and AP-1 leading to T cell nonresponse. 6 Deregulation of these molecules could lead to the loss of the tolerance driving an exacerbated activation and survivor of self-reactive T cells, leading to a lymphoproliferation which is characteristic in pSS. 7, 8 CD28 and CTLA4 genes are located in 2p33 chromosome and they are separated by 130 kb. 9 Both are composed by 4 exons and 3 introns. 10, 11 Soluble form of CD28 (sCD28) and CTLA-4 (sCTLA-4)
are originated due to alternative splicing of exon 3 deletion which codifies the transmembranal region. 10, 12, 13 In addition, CD28 could be shed from the cell surface being released in a soluble form. 14 Several studies have reported the presence of single nucleotide polymorphisms (SNPs) in both CD28 and CTLA4 genes, which could affect their expression and create isoforms of the respective protein.
The CD28 −372 G>A polymorphism (rs35593994) is found at the promoter region and could abolish the independent grow factor-1 site while the IVS3 + 17 T>C (rs3116496) is located into intron 3 near to splicing site and could create isoforms of the protein. 15 Among CTLA4 polymorphisms, −319 C>T (rs5742909) may affect the gene transcription due to alteration of the binding site of transcription factor-1, 16, 17 while +49 A>G (rs231775) at exon 1 codifies the leader sequence and affects the protein production, 18 and finally the +6230 G>A polymorphism (also known as CT60 G>A, rs3087243) is found in the 3′ UTR region at exon 4 and the G allele has been correlated with a reduction in mRNA levels of the soluble form. 19, 20 Many studies have associated individual CD28 and CTLA4 polymorphisms with autoimmune disease such as rheumatoid arthritis (RA) with high disease activity [21] [22] [23] [24] [25] and systemic lupus erythematosus (SLE) in which the −319 C>T polymorphism was associated with susceptibility, 26 high CTLA4 mRNA expression and sCTLA-4 levels. 27, 28 In primary Sjögren's syndrome the +49A/+6230G haplotype has been associated with susceptibility to the disease in Australian population 20 and also with high mRNA levels of CTLA4 in minor salivary glands of patients with pSS. 29 Based on the critical role of CD28 and CTLA-4 in the immune response and regulation of autoimmune process, the aim of this study was to associate CD28 and CTLA4 haplotypes with soluble levels and susceptibility in pSS patients from western Mexico. 
| MATERIAL AND ME THODS

| Subjects
| CD28 polymorphisms genotyping
Genomic DNA was extracted from total leukocytes of peripheral blood through Miller's modified technique. 34 The regions, which include CD28 polymorphisms, were amplified with the following primers: −372 G>A (rs35593994) 
| Haplotypes analysis
In order to estimate the haplotypes, their frequencies and to analyze the block structure, the online program SHEsis was used. 
| sCD28 and sCTLA-4 analysis
The soluble CD28 (sCD28) levels from pSS and CS were measure by human sCD28 ELISA kit (Affymetrix that have a sensibility of 0.13 ng/mL, the sCTLA-4 concentration was calculated with a standard curve which corresponds to recombinant human sCTLA-4. 
| Statistical analysis
| CD28 and CTLA4 polymorphic frequencies
The genotype frequencies were in Hardy-Weinberg equilibrium in all analyzed polymorphisms. The homozygous genotype was the most frequent in CD28 IVS3 + 17 T>C and CTLA4 −319 C>T polymorphisms in patients and control subjects. Moreover, the heterozygous genotype was the most frequent in the rest of studied polymorphisms. The presence of CD28 IVS3 + 17 C allele was associated with low risk to develop pSS (OR = 0.41, P < 0.001; dominant model OR = 0.51, P = 0.017) ( Table 2 ).
| Linkage disequilibrium (LD) and haplotype frequencies of CD28 and CTLA4
Block 
| CD28 and CTLA-4 serum levels
The soluble levels of CD28 and CTLA-4 were analyzed in pSS and CS. Soluble CD28 levels were similar in pSS and CS (1.3 vs 1.2 ng/ mL). The pSS patients carriers of CD28 IVS3 + 17 TC genotype showed high sCD28 levels (1.9 ng/mL vs CS TT carriers, P = 0.039).
No difference was observed between haplotype carriers ( Figure 2 and Table 4 ).
Primary Sjögren′s syndrome patients did not show difference in
sCTLA-4 levels (1.9 ng/mL vs CS = 1.99 ng/mL). When pSS patients were classified in relation to presence of CTLA4 −319 C>T, +49 A>G and +6230 G>A genotypes, no significant differences were found:
−319 (CT = 2.9 ng/mL vs CC = 1.7 ng/mL) and +49 (AA = 2.3 ng/mL vs CS GG = 1.0 ng/mL, and AG = 1.7 ng/mL vs CS GG = 1.0 ng/mL).
In regard to +6230 genotype carriers, no difference was observed ( Figure 3 ). The concentration of sCTLA-4 levels according to the four principal haplotypes in pSS did not show significant difference ( Figure 3 and Table 4 ).
| D ISCUSS I ON
The balance between stimulation and inhibition signals are important to keep immune tolerance and a disequilibrium in these signals are involved in pathogenesis of autoimmune diseases such as pSS; in this context CD28 and CTLA-4 are crucial to maintain this equilibrium. 29 CD28 is a glycoprotein required to activation, proliferation, and T cell survivor. 5 Several polymorphisms have been described in the CD28 gene. CTLA-4 is a transmembrane glycoprotein but unlike CD28, CTLA-4 participates in immune response regulation, mediation of antigen-specific apoptosis, inhibition of cell cycle progression and control of the T cells adaptation to anergy state and tolerance. 5, 6 Different polymorphisms have been reported in the CTLA4 gene like −319 C>T, +49 A>G, and +6230 G>A that have been associated with several autoimmune diseases. Observed and expected frequencies in all polymorphic sites were in Hardy-Weinberg equilibrium: −372 G>A (P = 0.673), IVS3+17 T>C (P = 0.699), −319 C>T (P = 0.172), +49 G>A (P = 0.338), and +6230 G>A (P = 0.387). Genotype and allele frequencies were compared by χ² test and P values were obtained by Fisher′s Exact Test when frequencies were lower than 5% and Pearson test when were higher than 5%. a Reference category.
polymorphism is located into intron 3 near of splicing site in CD28 gene and may influence the creation of isoforms of the protein. 35, 42 These polymorphisms have not been previously studied in pSS.
However, it has been reported that an association of T allele with RA, 21 as well as CT genotype with autoimmune thyroiditis 43 but association with SLE was not found. 40 The controversial results could be explained due to the genetic diversity of the studied populations and the role of CD28 in the physiopathology of each one of the autoimmune disease studied.
The gene segregation may occur in blocks and the effect of polymorphisms is stronger when analyzed by haplotype. CD28
haplotypes showed moderate LD (D' = 55, P < 0.001) and might be segregated in block 55% of the occasions ( Figure 1A ). The CD28 haplotypes from highest to the lower frequency were GT, AT, and GC. Soluble levels of CD28 did not show difference either in patients or in control subjects by genotype or haplotype in any analyzed polymorphism in this study, except in the IVS3 + 17 TC carriers who presented higher levels of this molecule. We showed that C allele had low risk to pSS perhaps participating in creating isoforms of the protein, particularly the soluble form due to closeness of this polymorphism to splicing site in the exon 3 which codifies to transmembrane domain (thus sCD28 could act as antagonist of their ligands (B7-1 and B7-2) blocking them and avoiding the binding in the membrane form which would lead to less activation). Different studies demonstrated that CD28 could be released in a soluble form due to alternative splicing lacking exon 3 which encodes the transmembrane region. 12, 13 However, it has been observed that CD28 also could be released through F I G U R E 2 Soluble Levels of CD28 in pSS Patients and Control Subjects. A, Soluble levels of CD28 in pSS and CS (P = 0.737); B, Soluble levels of CD28 according to genotypes of −372 G>A polymorphism (P = 0.232); C, Soluble levels of CD28 between carriers of IVS3+17 T>C genotypes (P = 0.012); D, Levels of sCD28 according to GT, AT and GC haplotype in pSS patients (P = 0.616). Haplotypes were inferred from homozygous subjects to CD28 polymorphisms. Differences between haplotypes were compared using Kruskal-Wallis with Dunn's test and Mann-Whitney U test. GT haplotype (−372G/IVS3+17T), AT haplotype (−372A/IVS3+17T), GC haplotype (−372G/IVS3+17C). pSS, primary Sjögren's syndrome; CS, control subjects to membrane cleavage. 15 Several studies have analyzed sCD28 levels in different autoimmune diseases obtaining different results. 14, 21, 41 Ledezma et al 21 showed increased soluble levels in RA patients, especially carriers of CD28 IVS3 + 17 TT genotype.
In Mexican patients with SLE carriers of CD28 -372 G>A polymorphism, no difference was shown. 41 Hebbar et al 14 in autoimmune diseases (RA, SLE, pSS) reported higher levels of sCD28 in pSS patients. Primary Sjögren′s syndrome patients with systemic disease showed higher sCD28 levels than patient with glandularlimited symptoms. 14 In addition, T cells of these patients expressed the full length transcript (encoding membrane CD28),
suggesting that sCD28 levels could be generated by shedding of membrane form.
14 With regard to CTLA4 polymorphisms, in this study the −319
C>T, +49 A>G and +6230 G>A polymorphisms did not show a difference in allelic and genotype frequencies in both groups. The −319 C>T and +6230 G>A polymorphisms were studied in Mexican population without association to rheumatoid arthritis. 22 Moreover, the +49 A>G polymorphism at exon 1 causes an aminoacid change binding. 44, 45 The relevance of CTLA-4 in the counter regulation of CD28 activated T cells including first, competition with CD28 for the receptors CD80 and CD86; second, CTLA-4 might deliver a negative signal to each T cell inhibiting the TCR signaling complex, and third, the effect exerted by Treg cells that express CTLA-4 and could be binded to CD80/CD86 on immature dendritic cells, leading to increase tryptophan catabolism and downregulation of T effector activity. 46 The reduction in mRNA expression levels that encodes sCTLA-4 could lead to reduced blockage of CD80/CD86, causing increased activation through CD28, or loss of stimulation of CD80/CD86 on immature dendritic cells, resulting in less tryptophan catabolism inhibition and lack of downregulation of T effector activity. 19 Infiltrated mononuclear cells in salivary glands of pSS patients express increased levels of CTLA-4 in circular areas resembling germinal centers or remnants of epithelial islands that are correlated with high mRNA levels (11.2-fold). 30 Furthermore, minor salivary gland biopsies reveal that focal lymphocytic infiltrates include mainly CD4 + T cells, some CD8 + T cells as well as macrophages, dendritic cells, and B-cells (~20% of the infiltrate). 46 These increased levels of CTLA-4 may implicate the regulation of cellular response in the local environment. In this context, the genetic variations in the CTLA4 gene could increase T cell selfreactivity in pSS patients.
In addition, the presence of CD28 and CTLA4 polymorphisms and their haplotypes, did not show the difference in clinical characteristics of pSS patients. The low frequency of anti-Ro and anti-La antibodies in pSS patients (24.5% and 13.2%, respectively) have been previously reported by our group 47 and by others. 48 It is possible that the low frequency of anti-Ro/anti-La antibodies could be a hallmark of some pSS patient as has been demonstrated in the Mexican population and in the French cohort. 47, 48 This finding confirms the relevance of the histopathology in the classification criteria for pSS, especially in patients with low frequency of anti-Ro antibodies (in our patients 98.2% and 24.5%, respectively).
In conclusion, the findings suggest that CD28 GC haplotype, CTLA4 CAG and CGA haplotypes are associated with susceptibility to develop pSS in patients from western Mexico. It seems that genetic control of CD28 and CTLA4 as well as the local immune response in the glandular tissue may regulate the impact of the gene expression in pSS. It is necessary to confirm these hypothesis in an integrative study that evaluates together the correlation between CD28 and CTLA4 haplotypes and its effects in salivary glands of pSS patients, in order to confirm the role in the physiopathology of the disease. 
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